OPERATING REVIEW CONTINUED FINANCE Summary Financials 2023 $’m 2022 $’m Revenue from contracts with customers 231.9 14.5 Interest income 5.7 0.4 Other income – 0.9 Foreign exchange gain 2.4 1.2 Total income 240.0 17.0 Research & Development (26.8) (12.7) Corporate & Administration (5.9) (3.4) Loss on financial derivatives measured at fair value (2.2) (0.7) Profit before tax 205.1 0.2 Income tax (48.0) – Profit after tax 157.1 0.2 Cash flow received from operations 184.9 3.6 Cash flow used in investing (211.5) – Cash flow received from financing 3.6 – Effect of exchange rates on cash balances (0.1) (0.2) Cash and short-term investments at 31 December 228.5 40.2 The consolidated financial statements are presented on pages 30 to 50. All amounts in the consolidated Financial Statements are shown in Australian dollars unless otherwise stated. 1 Cash and short-term investments Financial strength to maximise growth opportunities 7 40.2 26.8 59.4 145.7 5.7 2.5 -8.2 -26.8 -48.1 27.7 3.6 228.5 Dec 2022 Cash Royalty Milestone ex-NA upfront Interest Other income Other expenses R&D Tax Non cash adj Financing/ investing Dec 2023 Cash 2023 Profit After Tax A$157.1m A$m 1 Neuren Pharmaceuticals Limited Annual Report 2023 19
RkJQdWJsaXNoZXIy MjE2NDg3